The diabetic cardiomyopathy

Roberto Tarquini, Chiara Lazzeri, Laura Pala, Carlo Maria Rotella, Gian Franco Gensini

Research output: Contribution to journalArticle

Abstract

Diabetic cardiomyopathy has been defined as "a distinct entity characterized by the presence of abnormal myocardial performance or structure in the absence of epicardial coronary artery disease, hypertension, and significant valvular disease". The diagnosis stems from the detection of myocardial abnormalities and the exclusion of other contributory causes of cardiomyopathy. It rests on non-invasive imaging techniques which can demonstrate myocardial dysfunction across the spectra of clinical presentation. The presence of diabetes is associated with an increased risk of developing heart failure, and the 75% of patients with unexplained idiopathic dilated cardiomyopathy were found to be diabetic. Diabetic patients with microvascular complications show the strongest association between diabetes and cardiomyopathy, an association that parallels the duration and severity of hyperglycemia. Metabolic abnormalities (that is hyperglycemia, hyperinsulinemia, and hyperlipemia) can lead to the cellular alterations characterizing diabetic cardiomyopathy (that is myocardial fibrosis and/or myocardial hypertrophy) directly or indirectly (that is by means of renin-angiotensin system activation, cardiac autonomic neuropathy, alterations in calcium homeostasis). Moreover, metabolic abnormalities represent, on a clinical ground, the main therapeutic target in the patients with diabetes since the diagnosis of diabetes is made. Since diabetic cardiomyopathy is highly prevalent in the asymptomatic type 2 diabetic patients, screening for its presence at the earliest stage of development can lead to prevent the progression to chronic heart failure. The most sensitive test is standard echocardiogram, while a less expensive pre-screening method is the detection of microalbuminuria.

Original languageEnglish
Pages (from-to)173-181
Number of pages9
JournalActa Diabetologica
Volume48
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Diabetic Cardiomyopathies
Cardiomyopathies
Hyperglycemia
Heart Failure
Hyperinsulinism
Dilated Cardiomyopathy
Renin-Angiotensin System
Hyperlipidemias
Hypertrophy
Coronary Artery Disease
Homeostasis
Fibrosis
Hypertension
Calcium

Keywords

  • Diabetic cardiomyopathy
  • Pathophysiology
  • Prognosis

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Tarquini, R., Lazzeri, C., Pala, L., Rotella, C. M., & Gensini, G. F. (2011). The diabetic cardiomyopathy. Acta Diabetologica, 48(3), 173-181. https://doi.org/10.1007/s00592-010-0180-x

The diabetic cardiomyopathy. / Tarquini, Roberto; Lazzeri, Chiara; Pala, Laura; Rotella, Carlo Maria; Gensini, Gian Franco.

In: Acta Diabetologica, Vol. 48, No. 3, 09.2011, p. 173-181.

Research output: Contribution to journalArticle

Tarquini, R, Lazzeri, C, Pala, L, Rotella, CM & Gensini, GF 2011, 'The diabetic cardiomyopathy', Acta Diabetologica, vol. 48, no. 3, pp. 173-181. https://doi.org/10.1007/s00592-010-0180-x
Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetologica. 2011 Sep;48(3):173-181. https://doi.org/10.1007/s00592-010-0180-x
Tarquini, Roberto ; Lazzeri, Chiara ; Pala, Laura ; Rotella, Carlo Maria ; Gensini, Gian Franco. / The diabetic cardiomyopathy. In: Acta Diabetologica. 2011 ; Vol. 48, No. 3. pp. 173-181.
@article{8c9445046c374065871e32f2140150cc,
title = "The diabetic cardiomyopathy",
abstract = "Diabetic cardiomyopathy has been defined as {"}a distinct entity characterized by the presence of abnormal myocardial performance or structure in the absence of epicardial coronary artery disease, hypertension, and significant valvular disease{"}. The diagnosis stems from the detection of myocardial abnormalities and the exclusion of other contributory causes of cardiomyopathy. It rests on non-invasive imaging techniques which can demonstrate myocardial dysfunction across the spectra of clinical presentation. The presence of diabetes is associated with an increased risk of developing heart failure, and the 75{\%} of patients with unexplained idiopathic dilated cardiomyopathy were found to be diabetic. Diabetic patients with microvascular complications show the strongest association between diabetes and cardiomyopathy, an association that parallels the duration and severity of hyperglycemia. Metabolic abnormalities (that is hyperglycemia, hyperinsulinemia, and hyperlipemia) can lead to the cellular alterations characterizing diabetic cardiomyopathy (that is myocardial fibrosis and/or myocardial hypertrophy) directly or indirectly (that is by means of renin-angiotensin system activation, cardiac autonomic neuropathy, alterations in calcium homeostasis). Moreover, metabolic abnormalities represent, on a clinical ground, the main therapeutic target in the patients with diabetes since the diagnosis of diabetes is made. Since diabetic cardiomyopathy is highly prevalent in the asymptomatic type 2 diabetic patients, screening for its presence at the earliest stage of development can lead to prevent the progression to chronic heart failure. The most sensitive test is standard echocardiogram, while a less expensive pre-screening method is the detection of microalbuminuria.",
keywords = "Diabetic cardiomyopathy, Pathophysiology, Prognosis",
author = "Roberto Tarquini and Chiara Lazzeri and Laura Pala and Rotella, {Carlo Maria} and Gensini, {Gian Franco}",
year = "2011",
month = "9",
doi = "10.1007/s00592-010-0180-x",
language = "English",
volume = "48",
pages = "173--181",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer-Verlag Italia s.r.l.",
number = "3",

}

TY - JOUR

T1 - The diabetic cardiomyopathy

AU - Tarquini, Roberto

AU - Lazzeri, Chiara

AU - Pala, Laura

AU - Rotella, Carlo Maria

AU - Gensini, Gian Franco

PY - 2011/9

Y1 - 2011/9

N2 - Diabetic cardiomyopathy has been defined as "a distinct entity characterized by the presence of abnormal myocardial performance or structure in the absence of epicardial coronary artery disease, hypertension, and significant valvular disease". The diagnosis stems from the detection of myocardial abnormalities and the exclusion of other contributory causes of cardiomyopathy. It rests on non-invasive imaging techniques which can demonstrate myocardial dysfunction across the spectra of clinical presentation. The presence of diabetes is associated with an increased risk of developing heart failure, and the 75% of patients with unexplained idiopathic dilated cardiomyopathy were found to be diabetic. Diabetic patients with microvascular complications show the strongest association between diabetes and cardiomyopathy, an association that parallels the duration and severity of hyperglycemia. Metabolic abnormalities (that is hyperglycemia, hyperinsulinemia, and hyperlipemia) can lead to the cellular alterations characterizing diabetic cardiomyopathy (that is myocardial fibrosis and/or myocardial hypertrophy) directly or indirectly (that is by means of renin-angiotensin system activation, cardiac autonomic neuropathy, alterations in calcium homeostasis). Moreover, metabolic abnormalities represent, on a clinical ground, the main therapeutic target in the patients with diabetes since the diagnosis of diabetes is made. Since diabetic cardiomyopathy is highly prevalent in the asymptomatic type 2 diabetic patients, screening for its presence at the earliest stage of development can lead to prevent the progression to chronic heart failure. The most sensitive test is standard echocardiogram, while a less expensive pre-screening method is the detection of microalbuminuria.

AB - Diabetic cardiomyopathy has been defined as "a distinct entity characterized by the presence of abnormal myocardial performance or structure in the absence of epicardial coronary artery disease, hypertension, and significant valvular disease". The diagnosis stems from the detection of myocardial abnormalities and the exclusion of other contributory causes of cardiomyopathy. It rests on non-invasive imaging techniques which can demonstrate myocardial dysfunction across the spectra of clinical presentation. The presence of diabetes is associated with an increased risk of developing heart failure, and the 75% of patients with unexplained idiopathic dilated cardiomyopathy were found to be diabetic. Diabetic patients with microvascular complications show the strongest association between diabetes and cardiomyopathy, an association that parallels the duration and severity of hyperglycemia. Metabolic abnormalities (that is hyperglycemia, hyperinsulinemia, and hyperlipemia) can lead to the cellular alterations characterizing diabetic cardiomyopathy (that is myocardial fibrosis and/or myocardial hypertrophy) directly or indirectly (that is by means of renin-angiotensin system activation, cardiac autonomic neuropathy, alterations in calcium homeostasis). Moreover, metabolic abnormalities represent, on a clinical ground, the main therapeutic target in the patients with diabetes since the diagnosis of diabetes is made. Since diabetic cardiomyopathy is highly prevalent in the asymptomatic type 2 diabetic patients, screening for its presence at the earliest stage of development can lead to prevent the progression to chronic heart failure. The most sensitive test is standard echocardiogram, while a less expensive pre-screening method is the detection of microalbuminuria.

KW - Diabetic cardiomyopathy

KW - Pathophysiology

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=80052355062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052355062&partnerID=8YFLogxK

U2 - 10.1007/s00592-010-0180-x

DO - 10.1007/s00592-010-0180-x

M3 - Article

C2 - 20198391

AN - SCOPUS:80052355062

VL - 48

SP - 173

EP - 181

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 3

ER -